Skip to content

Investigation of KLYX in Patients With Constipation

Efficacy and Safety of KLYX Versus Glycerine Enema in Chinese Patients With Constipation - a Randomised, Assessor-blind Pilot Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01335386
Enrollment
60
Registered
2011-04-14
Start date
2010-04-30
Completion date
2010-07-31
Last updated
2012-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation

Brief summary

This is a randomised, assessor-blind, multi-centre pilot study to investigate the comparative safety and efficacy of KLYX and glycerine enema in the symptomatic treatment of constipation in Chinese patients.

Interventions

DRUGKLYX

Sponsors

Ferring Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Have signed the informed consent form and have been verbally explained the details of the trial and treatment procedures * Ethnically Chinese * Males or females aged between 18 and 65 years inclusive * A history of constipation symptoms for at least 6 months fulfilling, with occurrence of two or more of the following symptoms during the 3 months before screening (the 3 months need not be consecutive): i. Very hard (pellet-like) and/or hard stools (Type 1 or 2 of the Bristol Stool Scale) for at least 25% of the time; or ii. Sensation of incomplete evacuation at least 25% of the time; or iii. Straining during defecation at least 25% of the time; or iv. Sensation of anorectal obstruction or blockage often during defecation at least 25% of the time; or v. Manual manoeuvres needed often to facilitate defecations (e.g. digital evacuation, support of the pelvic floor) at least 25% of the time; or vi. Fewer than 3 defecations per week. * Patient has had no bowel movement (i.e. still constipated) two days prior randomisation.

Exclusion criteria

* Any disorder or laboratory result at Screening that in the judgement of the investigator that will place the subject at excessive risk if participating in a controlled study * Clinically suspected to have colorectal cancer * Significant gastroparesis or gastric outlet obstruction * Hypersensitivity to sodium docusate and/or sorbitol * Hypersensitivity to glycerine * Pregnant or lactating women, women who intend to conceive, or women who are sexually active and capable of pregnancy who are not using a method of birth control (e.g. prescription hormonal contraceptives, intrauterine device, double-barrier method, male partner sterilization) * Diabetic patients currently on insulin therapy * Having participated in other clinical trial(s) within the 3 (three) months prior screening * Unable to withdraw medications that may affect gastrointestinal motility such as prokinetics, erythromycin analogues, laxatives, etc. * Unable to meet or perform study requirements: known or suspected inability to comply with the study protocol

Design outcomes

Primary

MeasureTime frame
Overall efficacy of enemaimmediately following enema administration

Secondary

MeasureTime frame
Time to first bowel movementImmediately following enema administration
Patient's overall satisfaction with enema treatmentImmediately following enema administration
Stool form after enema treatmentImmediately following enema administration

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026